Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
D000818:Animals; D019138:Antibodies, Blocking / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology*; D002352:Carrier Proteins / Q000378:metabolism; D002356:Cartilage / Q000187:drug effects / Q000473:pathology*; D002460:Cell Line; D019902:Chondrocytes / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D006614:Hindlimb / Q000187:drug effects / Q000473:pathology; D007167:Immunotherapy; D007375:Interleukin-1 / Q000378:metabolism; D020381:Interleukin-17 / Q000037:antagonists & inhibitors / Q000276:immunology*; D015850:Interleukin-6 / Q000097:blood; D007596:Joints / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D051379:Mice; D008811:Mice, Inbred DBA; D053245:RANK Ligand; D011817:Rabbits; D053246:Receptor Activator of Nuclear Factor-kappa B; D013583:Synovial Membrane / Q000187:drug effects / Q000378:metabolism
D019138:Antibodies, Blocking; D002352:Carrier Proteins; D007375:Interleukin-1; D020381:Interleukin-17; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505687:Tnfrsf11a protein, mouse; C505689:Tnfsf11 protein, mouse